Plus Therapeutics Appoints Russell Bradley as CNSide Diagnostics President

Plus Therapeutics has announced key leadership appointments at its subsidiary, CNSide Diagnostics LLC, as it advances innovative diagnostic solutions for CNS cancer patients. Russell Bradley, a seasoned executive with 30 years of experience in life sciences diagnostics, has been appointed President and General Manager. Having held leadership roles at Abbott Laboratories, Luminex Corporation, and Beckman Coulter, Bradley brings a proven track record in global growth strategies and business transformation. Alongside his new role, he joins the CNSide Board of Directors with Dr. Marc Hedrick and Rick Hawkins.

Additionally, Dr. Jonathan Stein has been named Medical Director, bringing over 20 years of expertise in molecular diagnostics and oncology testing. His previous roles at Gene By Gene and M.D. Anderson Cancer Center highlight his deep knowledge of assay development and regulatory compliance. These appointments come as CNSide prepares for its U.S. market pilot launch, with Bradley emphasizing the critical need for improved testing tools for leptomeningeal disease. His leadership is set to drive early access initiatives and commercial growth in the CNS diagnostics space.